The landscape of care for early-stage non–small cell lung cancer continues to evolve. While
some of the developments do not seem as dramatic as what has occurred in advanced …

Lung cancer is the leading cause of cancer-related deaths in China, with over 690 000 lung
cancer deaths estimated in 2018. The mortality has increased about five-fold from the mid …

The 2010's saw demonstration of the power of lung cancer screening to reduce mortality.
However, with implementation of lung cancer screening comes the challenge of diagnosing …

Background Approximately 21 900 women and 35 300 men developed lung cancer in
Germany in 2018, and 16 514 women and 28 365 men died of it. The outcome mainly …

Abstract Background The US National Lung Screening Trial (NLST) and Dutch‐Belgian
NELSON randomized controlled trials have shown significant mortality reductions from low …

Objectives Cardiovascular disease (CVD), lung cancer (LC), and respiratory diseases are
main causes of death in smokers and former smokers undergoing low-dose computed …

The ITALUNG trial started in 2004 and compared lung cancer (LC) and other-causes
mortality in 55–69 years-aged smokers and ex-smokers who were randomized to four …

Objetivo. Proporcionar recomendaciones para la detección temprana de pacientes con alto
riesgo de desarrollar cáncer de pulmón (CP) en el primer nivel de atención y su referencia …

Asymptomatic high‐risk subjects, randomized in the intervention arm of the ITALUNG trial
(1,406 screened for lung cancer), were enrolled for the ITALUNG biomarker study (n …

Objectives T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) is a promising
checkpoint. However, its features and prognostic value in lung adenocarcinoma remain …